UY28760A1 - Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico - Google Patents
Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópicoInfo
- Publication number
- UY28760A1 UY28760A1 UY28760A UY28760A UY28760A1 UY 28760 A1 UY28760 A1 UY 28760A1 UY 28760 A UY28760 A UY 28760A UY 28760 A UY28760 A UY 28760A UY 28760 A1 UY28760 A1 UY 28760A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- antagonists
- metabotropic glutamate
- receiver
- triazol compounds
- Prior art date
Links
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54528904P | 2004-02-18 | 2004-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28760A1 true UY28760A1 (es) | 2005-06-30 |
Family
ID=34886127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28760A UY28760A1 (es) | 2004-02-18 | 2005-02-18 | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20070185178A1 (https=) |
| EP (1) | EP1720860A1 (https=) |
| JP (1) | JP2007523178A (https=) |
| KR (1) | KR20070027503A (https=) |
| CN (1) | CN101018779A (https=) |
| AR (1) | AR047744A1 (https=) |
| AU (1) | AU2005214375A1 (https=) |
| BR (1) | BRPI0507501A (https=) |
| CA (1) | CA2554894A1 (https=) |
| EA (1) | EA200601266A1 (https=) |
| IL (1) | IL177057A0 (https=) |
| NO (1) | NO20063468L (https=) |
| RU (1) | RU2006127575A (https=) |
| TW (1) | TW200604183A (https=) |
| UY (1) | UY28760A1 (https=) |
| WO (1) | WO2005080379A1 (https=) |
| ZA (1) | ZA200606313B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| BRPI0818448A2 (pt) * | 2007-10-19 | 2015-05-12 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5. |
| WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
| TW200922585A (en) * | 2007-10-26 | 2009-06-01 | Astrazeneca Ab | Amino 1,2,4-triazole derivatives as modulators of mGluR5 |
| WO2009054790A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
| CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| US20100114146A1 (en) * | 2008-10-30 | 2010-05-06 | Albrecht Thomas E | Methods and devices for predicting intra-gastric satiety and satiation creation device system performance |
| BRPI0923215A2 (pt) * | 2008-12-12 | 2017-06-06 | Astrazeneca Ab | método para fabricar um composto. |
| EP2379531A1 (en) * | 2008-12-18 | 2011-10-26 | AstraZeneca AB | Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| EP2638035B1 (en) * | 2010-11-09 | 2014-12-17 | F.Hoffmann-La Roche Ag | Triazole derivatives as ligands for Gaba receptors |
| EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | 三唑酮化合物及其应用 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| SG10202103278TA (en) | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| CA3143103A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
| MX2021015511A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4303109B2 (ja) * | 2001-10-04 | 2009-07-29 | メルク エンド カムパニー インコーポレーテッド | 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤 |
| WO2003037274A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| US7074809B2 (en) * | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| WO2004014881A2 (en) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
-
2005
- 2005-02-17 RU RU2006127575/04A patent/RU2006127575A/ru not_active Application Discontinuation
- 2005-02-17 EP EP05723281A patent/EP1720860A1/en not_active Withdrawn
- 2005-02-17 EA EA200601266A patent/EA200601266A1/ru unknown
- 2005-02-17 TW TW094104645A patent/TW200604183A/zh unknown
- 2005-02-17 AU AU2005214375A patent/AU2005214375A1/en not_active Abandoned
- 2005-02-17 CN CNA2005800102818A patent/CN101018779A/zh active Pending
- 2005-02-17 JP JP2006554231A patent/JP2007523178A/ja active Pending
- 2005-02-17 US US10/588,751 patent/US20070185178A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507501-7A patent/BRPI0507501A/pt not_active IP Right Cessation
- 2005-02-17 WO PCT/US2005/005200 patent/WO2005080379A1/en not_active Ceased
- 2005-02-17 KR KR1020067015941A patent/KR20070027503A/ko not_active Withdrawn
- 2005-02-17 CA CA002554894A patent/CA2554894A1/en not_active Abandoned
- 2005-02-17 AR ARP050100570A patent/AR047744A1/es not_active Application Discontinuation
- 2005-02-18 US US11/060,366 patent/US20060019997A1/en not_active Abandoned
- 2005-02-18 UY UY28760A patent/UY28760A1/es unknown
-
2006
- 2006-07-25 IL IL177057A patent/IL177057A0/en unknown
- 2006-07-28 NO NO20063468A patent/NO20063468L/no not_active Application Discontinuation
- 2006-07-28 ZA ZA200606313A patent/ZA200606313B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200606313B (en) | 2007-03-28 |
| CA2554894A1 (en) | 2005-09-01 |
| EP1720860A1 (en) | 2006-11-15 |
| KR20070027503A (ko) | 2007-03-09 |
| BRPI0507501A (pt) | 2007-06-26 |
| NO20063468L (no) | 2006-11-15 |
| AR047744A1 (es) | 2006-02-15 |
| CN101018779A (zh) | 2007-08-15 |
| JP2007523178A (ja) | 2007-08-16 |
| US20070185178A1 (en) | 2007-08-09 |
| AU2005214375A1 (en) | 2005-09-01 |
| EA200601266A1 (ru) | 2007-02-27 |
| WO2005080379A1 (en) | 2005-09-01 |
| IL177057A0 (en) | 2006-12-10 |
| TW200604183A (en) | 2006-02-01 |
| RU2006127575A (ru) | 2008-03-27 |
| US20060019997A1 (en) | 2006-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
| UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
| UY28764A1 (es) | Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico | |
| MY152888A (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists. | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| CR9814A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
| CU20110204A7 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| ECSP077236A (es) | Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos | |
| MX388468B (es) | Compuestos multicíclicos y métodos de uso de los mismos. | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| ECSP077233A (es) | Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos | |
| CL2008000905A1 (es) | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. | |
| HN2008001530A (es) | Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| CL2008003591A1 (es) | Compuestos derivados de isoxazolo-piridina sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos y alzheimer, mediado por la union al sitio de fijacion del receptor gaba a alfa 5. | |
| UY31071A1 (es) | Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones | |
| CO6420342A2 (es) | Derivados de pirazol usados como antagonistas del receptor ccr4 | |
| CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
| PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| UY29988A1 (es) | Compuestos de oxazolidinona y su uso como potenciadores del receptor metabotrópico de glutamato | |
| CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
| CL2004000553A1 (es) | Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende. | |
| ECSP12011904A (es) | Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1. | |
| SV2005002061A (es) | Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538 | |
| UY32520A (es) | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides |